** Shares of Neuren Pharmaceuticals NEU.AX up 16% at A$10.7, their biggest intraday percentage gain since December 18, 2023
** Stock is top gainer in the ASX 200 benchmark index .AXJO, which is up 0.6%
** The drugmaker says primary endpoints for its Phase 3 trial of NNZ-2591 in Phelan-McDermid syndrome (PMS), a genetic disorder, confirmed at a meeting with the U.S. Food and Drug Administration
** Stock down 26.5% this year, as of last close
(Reporting by Sherin Sunny in Bengaluru)
((Sherin.Sunny@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。